Work

Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA.

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.15_suppl.tps602

Authors: Frederik Marmé, Elmar Stickeler, Jenny Furlanetto, Carsten Denkert, Marcus Schmidt, Mattea Reinisch, Toralf Reimer, Wolfgang Janni, Michael Untch, Bruno Valentin Sinn, Volker Moebus, Laura Michel, Laura Schoellhorn, Sabine Schmatloch, Julia Rey, Sibylle Loibl

Institutions: Heidelberg University, Medizinische Fakultät Mannheim, RWTH Aachen University, German Breast Group, Philipps University of Marburg, University Medical Center of the Johannes Gutenberg University Mainz, Kliniken Essen-Mitte, University of Rostock, Universität Ulm, Helios Hospital Berlin-Buch, The University of Texas MD Anderson Cancer Center, Goethe University Frankfurt, National Center for Tumor Diseases

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Gilead Sciences

OpenAlex ID: W3172025938

Cites:

Cited by: 27

Related to: 10